Marketing: Page
-
FDA targets illegal online pharmacies as part of global crackdown
In a recent enforcement effort, the U.S. regulator sent 13 warning letters to the operators of 401 websites peddling illegal or counterfeit medicines.
By Suzanne Elvidge • Sept. 27, 2017 -
AbbVie to keep limits on price hikes next year, denying backtrack
Pressure ratcheted up on AbbVie after reports suggested the drugmaker was considering returning to double-digit price increases in 2018.
By Ned Pagliarulo • Sept. 27, 2017 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
J&J, Roche among companies selected for FDA digital health pilot
The regulator hopes to improve how it reviews digital medical devices, aiming to streamline the path to market for new health tools.
By Jeff Byers • Sept. 26, 2017 -
What you need to know: The evolving pharma sales force
BioPharma Dive's latest Spotlight examines how the pressures of shifting markets, patent expirations and industry restructurings have impacted sales forces.
By Lisa LaMotta • Sept. 26, 2017 -
Premium price for Novartis' CAR-T sparks pushback from top PBM
The healthcare system is not equipped to pay for personalized, one-time treatments like Novartis' newly approved Kyrmiah, says Express Scripts.
By Ned Pagliarulo • Sept. 25, 2017 -
Judge denies PhRMA, BIO jab at Nevada law
The trade groups didn't convince Judge James Mahan that a temporary restraining order was warranted for the state's diabetes drug pricing transparency bill.
By Jacob Bell • Sept. 20, 2017 -
House members urge Trump to lower cost of opioid overdose antidote
Prices of new naloxone formulations, such as Kaleo's Evzio, have risen in recent years, drawing scrutiny from lawmakers.
By Suzanne Elvidge • Sept. 20, 2017 -
Bayer ends sales of Essure implant outside of US
The drugmaker said the decision was unrelated to the safety or efficacy of the contraceptive, which has been the subject of numerous consumer complaints.
By Ned Pagliarulo • Sept. 19, 2017 -
Split adcomm vote leaves Pfizer's Sutent in limbo
An FDA advisory panel voted six in favor, six against a new indication for the drugmaker's cancer med.
By Jacob Bell • Sept. 19, 2017 -
Deep Dive
Digital pharma sales technologies soar
Digital contact with physicians has changed the role of the sales rep and made it easier to track patient data.
By Malorye Allison Branca • Sept. 18, 2017 -
Deep Dive
5 Trends shaping the pharma sales force
Many factors have played a role in shrinking the pharma sales force. But sales reps aren't going away — their role is just changing.
By Lisa LaMotta • Sept. 18, 2017 -
Elizabeth Regan/BioPharma Dive
Deep DiveHow to optimize pharma sales forces in a changing marketplace
Less time with doctors, an increase in rare disease drugs and higher use of digital tools means it's important to find the right talent and use reps efficiently.
By Jacob Bell • Sept. 18, 2017 -
Deep Dive
Smaller sales forces get the job done in rare disease
The shift from primary care to specialty medicines has meant rightsizing sales forces to match markets.
By Ned Pagliarulo • Sept. 18, 2017 -
Elizabeth Regan/BioPharma Dive
Infographic: Pharma sales force by the numbers
As sales forces have shrunk across the industry, pharma is looking to new ways to reach physicians.
By Jordan Branch , Lisa LaMotta • Sept. 18, 2017 -
Bayer's PI3K inhibitor secures FDA approval
The regulatory OK was supported by a mid-stage study which showed efficacy in heavily pretreated patients with follicular lymphoma.
By Jacob Bell • Sept. 15, 2017 -
Amgen, Allergan win first approval of cancer biosimilar in US
The drug, which will be marketed as Mvasi, is a biosimilar version of Roche's top-selling biologic Avastin.
By Ned Pagliarulo • Sept. 14, 2017 -
New estimate puts cost to develop a cancer drug at $648M
An analysis published in JAMA found that developing cancer drugs may cost significantly less than previously thought.
By Lisa LaMotta • Sept. 13, 2017 -
Sponsored by ZS Associates
Taking the long view on pharma's reputation management
To start chipping away at pharma’s reputation problem, companies should consider tapping their internal brand champions — and equipping them for success.
By Pratap Khedkar • Sept. 13, 2017 -
ICER analysis latest salvo in debate over Repatha price
Amgen's cholesterol drug would need to cost between 85% and 88% less than its current list price to meet the research group's value-based benchmark.
By Ned Pagliarulo • Sept. 12, 2017 -
FDA warns drugmaker over misleading marketing of opioid
The regulator's letter to Cipher Pharmaceuticals is only the second warning issued by the Office of Prescription Drug Promotion this year.
By Ned Pagliarulo • Sept. 6, 2017 -
Mallinckrodt tumbles after judge invalidates Inomax patents
The decision favors Praxair, which is developing a copycat version of the drug.
By Jacob Bell • Sept. 6, 2017 -
FDA delays review of Mylan and Biocon's Herceptin biosimilar
The companies had appeared set for a September approval after winning the backing of an FDA panel, but a final decision will now not come until December.
By Suzanne Elvidge • Sept. 6, 2017 -
Novo Nordisk settles claims related to Victoza marketing
Without admitting fault, the Danish drugmaker will pay out $58 million to settle claims related to marketing of its best-selling drug.
By Lisa LaMotta • Sept. 6, 2017 -
Industry Pulse: 10 charts on M&A, I/O and biosimilar threats
While Gilead's acquisition of Kite lifted the biotech sector, major dealmaking has been few and far between this year. Elsewhere, copycat biologics pose a growing threat to industry top-sellers.
By Ned Pagliarulo • Sept. 1, 2017 -
Pfizer's Mylotarg gets a second shot at market
After being withdrawn in 2010, the cancer drug has been green lighted again with new dosing and a slightly different patient population.
By Lisa LaMotta • Sept. 1, 2017
Previous
